Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities – a register-based retrospective cohort study in Finland

Table 3 Proportion of use of lipid lowering medication by different patient group

	only T2D (n = 4440)			T2D + CVD (n = 2544)			T2D + AMD (n = 942)			T2D + CVD + AMD (n = 503)
	2011-12	2015-16	P-value	2011-12	2015-16	P-value	2011-12	2015-16	P-value	2011-12	2015-16	P-value
Medication group:
No therapy	37	30	< 0.001	18	14	< 0.001	40	36	< 0.001	31	29	0.204
Low intensity	8	8	0.004	9	7	0.003	8	7	0.354	8	5	0.022
Moderate intensity	50	54	< 0.001	57	56	0.178	49	52	0.048	48	50	0.215
High intensity	5	9	< 0.001	16	22	< 0.001	3	5	< 0.001	14	16	0.058

P-value from the logistic regression models with generalized estimating equations (GEE) for the changes in the use of lipid lowering medications from baseline (2011-12) to follow-up (2015-16) by different patient groups. Adjustment with age and sex did not change the P-value. CVD = cardiovascular disease (I20-I25, I46, I48, I50, I63-I66 (except I63.6) and G45), AMD = any mental disorder (ICD-10 code F00-F03, F20-F48 & G30)

ISSN: 2731-4553